The Arto transcatheter mitral valve repair system

Andrejs Erglis¹, MD, PhD; Martyn Thomas², MD; Marie-Claude Morice³, MD; Inga Narbute¹, MD; Milana Zabunova¹, MD; Thomas Hovasse², MD; Mathieu Poupineau⁴, MD; Ainars Rudzitis¹, MD; Ginta Kamzola¹, MD; Ligita Zvaigzne¹, MD; Samantha Greene⁵, BA; Jason H. Rogers*, MD

1. Latvian Centre of Cardiology, Pauls Stradiņš Clinical University Hospital, Riga, Latvia; 2. Guy’s and St Thomas’ Hospital, London, United Kingdom; 3. Générale de Santé, Institut Cardiovasculaire Paris Sud, Massy, France; 4. Cardiology Department, Centre Hospitalier Privé, Claude Galien, Quincy-sous-Sénart, France; 5. MVRx Inc., Belmont, CA, USA; 6. Division of Cardiovascular Medicine, University of California, Davis Medical Center, Sacramento, CA, USA

Device description

Name and manufacturer: Arto™ System; MVRx, Inc., Belmont, CA, USA.
Approval status: Clinical evaluation.
Platform: Left atrial-based mitral valve repair.
Specific design: Anterior-posterior (A-P) annulus shortening of native mitral valve.
Delivery approach: Endovascular venous delivery.
Device size: 12 Fr delivery system.

Procedural details

The procedures were carried out under general anaesthesia with transoesophageal echocardiographic (TEE) guidance. The procedure has been described in detail previously¹,² and is shown in Figure 1.

Clinical data

Eleven consecutive patients had successful implantation of the Arto System in the MitrAl ValvE Repair Clinical Trial (MAVERIC Trial, clinicaltrials.gov identifier NCT02302872). The demographics and outcomes have been published previously³. All patients were deemed to be high surgical risk by the Heart Team, and were symptomatic with 81.8% being NYHA Class III/IV at baseline. There were no procedural safety events in any patient. There were two clinical events within the 30-day follow-up period: (1) one patient underwent uncomplicated surgical drainage of the effusion without recurrence, and (2) one patient had asymptomatic dislocation of the coronary sinus T-bar and underwent successful elective surgical MV replacement. No other clinical events have occurred at subsequent follow-ups.

At six months, MR grade, LV volumes, mitral annular dimensions, and functional status all improved, and were very stable when compared to 30-day values. Pre-procedure FMR was 90% grade 3-4+, and at six months was 80% grade 1-2+. EROA by PISA at baseline was 30.3±11.1, decreasing at six months to 13.7±8.6 mm², and regurgitant volumes decreased from 45.4±15.0 to 19.9±11.6 ml. LVESVi decreased from 77.5±24.3 to 68.2±28.2 mL/m² and LVEDVi from 118.7±28.6 to 104.9±30.2 ml/m² at six months. Mitral annular anteroposterior diameter decreased from 45.0±3.3 to 38.9±2.7 mm. Functional status was 81.8% NYHA Class III/IV and 18.2% Class I/II at baseline, improving at six months to 50.0% Class III and 50.0% Class I/II.

Ongoing studies

Enrolment of up to 20 additional patients at three sites (Riga, Latvia; Massy, France and London, United Kingdom) is expected to begin shortly in Phase II of the MAVERIC trial.

Unique features

Unique features of the Arto System include the relatively short procedure time, as well as the absence of haemodynamic instability or ventricular arrhythmias. Device efficacy is seen immediately at the time of implantation, and the system can be adjusted by tensioning or relaxing the suture element prior to device lock and release. The Arto System is recapturable and retrievable during the deployment.

Potential improvements

With additional patient outcomes data, the preferred placement of the anchors for a given anatomy as well as the preferred amount of A-P shortening will be known and result in maximising benefits to the patient. System improvements include the addition of new anchor designs and streamlining of the catheter delivery system.
Conflict of interest statement

J. Rogers, M. Thomas, and S. Greene are consultants to MVRx. A. Erglis has an indirect equity interest in MVRx. The other authors have no conflicts of interest to declare.

References

